ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other Events

ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

On June4, 2018, Andrew I. Koven, the President and Chief Business Officer of Aralez Pharmaceuticals Inc. (the “Company”), executed a “sell-to-cover” transaction to which he sold common shares of the Company for payment of withholding tax liability incurred upon the vesting of restricted stock units (“RSUs”), which were previously granted on June3, 2015 and which vested on June3, 2018. Mr.Koven’s sale of these securities was completed to a previously made election and consistent with his past practice of selling securities upon vesting of RSUs to pay withholding tax obligations.


About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

An ad to help with our costs